L Lorenzo-Luaces1,2, J D Amsterdam1, I Soeller1,3, R J DeRubeis1,2. 1. Depression Research Unit, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia, PA. 2. Department of Psychology, University of Pennsylvania, Philadelphia, PA. 3. Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Abstract
OBJECTIVE: To examine the safety and effectiveness of antidepressant versus mood stabilizer monotherapy in rapid versus non-rapid cycling bipolar II disorder. METHOD: Subjects ≥18 years old with bipolar II depression (n = 129) were randomized to double-blind venlafaxine or lithium carbonate monotherapy for 12 weeks. Responders (n = 59) received continuation monotherapy for six additional months. RESULTS: Rapid cycling did not affect frequency of response or change over time in depressive symptoms. Rapid cycling status did not affect frequency of depressive relapse or sustained treatment response. Rapid cyclers were more likely to experience hypomanic symptoms (P = 0.005) during continuation monotherapy; however, rates were similar in venlafaxine (17.6%) and lithium (42.9%) (P = 0.31). CONCLUSION: Rapid cycling status may not be associated with an increased risk of diminished response or greater depressive relapse during venlafaxine, relative to lithium monotherapy, in bipolar II subjects. Additional randomized studies are needed to confirm these findings.
RCT Entities:
OBJECTIVE: To examine the safety and effectiveness of antidepressant versus mood stabilizer monotherapy in rapid versus non-rapid cycling bipolar II disorder. METHOD: Subjects ≥18 years old with bipolar II depression (n = 129) were randomized to double-blind venlafaxine or lithium carbonate monotherapy for 12 weeks. Responders (n = 59) received continuation monotherapy for six additional months. RESULTS: Rapid cycling did not affect frequency of response or change over time in depressive symptoms. Rapid cycling status did not affect frequency of depressive relapse or sustained treatment response. Rapid cyclers were more likely to experience hypomanic symptoms (P = 0.005) during continuation monotherapy; however, rates were similar in venlafaxine (17.6%) and lithium (42.9%) (P = 0.31). CONCLUSION: Rapid cycling status may not be associated with an increased risk of diminished response or greater depressive relapse during venlafaxine, relative to lithium monotherapy, in bipolar II subjects. Additional randomized studies are needed to confirm these findings.
Authors: D J Kupfer; K N Chengappa; A J Gelenberg; R M Hirschfeld; J F Goldberg; G S Sachs; V J Grochocinski; P R Houck; A B Kolar Journal: J Clin Psychiatry Date: 2001-12 Impact factor: 4.384
Authors: William Coryell; David Solomon; Carolyn Turvey; Martin Keller; Andrew C Leon; Jean Endicott; Pamela Schettler; Lewis Judd; Timothy Mueller Journal: Arch Gen Psychiatry Date: 2003-09
Authors: S Nassir Ghaemi; Klara J Rosenquist; James Y Ko; Claudia F Baldassano; Nicholas J Kontos; Ross J Baldessarini Journal: Am J Psychiatry Date: 2004-01 Impact factor: 18.112
Authors: A Koukopoulos; G Sani; A E Koukopoulos; G P Minnai; P Girardi; L Pani; M J Albert; D Reginaldi Journal: J Affect Disord Date: 2003-01 Impact factor: 4.839
Authors: Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller Journal: Int J Neuropsychopharmacol Date: 2017-02-01 Impact factor: 5.176